ChitogenX Inc. (CHNXF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerChitogenX Inc. (CHNXF) trades at $0.00755. ChitogenX Inc. is a Canadian orthopaedic and sports medicine biologics company focused on developing soft tissue repair technologies. Their lead product candidates target rotator cuff, meniscus, articular cartilage, osteoarthritis, and tendon injuries. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for CHNXF: CHNXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CHNXF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Dated analysis: the newest financial statements on file are 23 months old (Oct 1, 2024), so the figures and score below describe that period, not today.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
CHNXF: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
ChitogenX Inc. (CHNXF) Healthcare & Pipeline Overview
ChitogenX Inc. is a biotechnology company developing novel therapeutic soft tissue repair technologies for the orthopaedic and sports medicine market. Their pipeline focuses on biopolymer formulations like Ortho-R and Ortho-M, aiming to improve surgical outcomes for common sports-related injuries in Canada.
What Is the Investment Thesis for CHNXF?
ChitogenX presents a speculative investment opportunity within the orthopaedic biologics space. The company's focus on soft tissue repair technologies, particularly its Ortho-R and Ortho-M formulations, addresses a significant market need. Successful clinical trials and regulatory approvals could drive substantial value. However, the company's OTC listing and limited financial data necessitate careful due diligence. Key catalysts include upcoming clinical trial results and potential partnerships. The negative P/E ratio of -0.23 reflects the company's current lack of profitability, typical for early-stage biotech firms. Investors should closely monitor cash burn and potential dilution. The beta of -2.19 suggests the stock is less volatile than the market, but this may be due to low trading volume.
Based on FMP financials and quantitative analysis
CHNXF Key Highlights
Focus on orthopaedic and sports medicine biologics, a growing area within healthcare.
- Development of Ortho-R for rotator cuff repair, targeting a large market segment.
- Pipeline includes Ortho-M, Ortho-C, Ortho-V, and Ortho-T, addressing multiple soft tissue injuries.
- Relatively young company, incorporated in 2015, indicating potential for high growth but also higher risk.
- Trades on the OTC market, which presents both opportunities and challenges for investors.
Who Are CHNXF's Competitors?
CHNXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| NVO Novo Nordisk A/S | $44.01 | -1.23% | $195B | 925-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $514.90 | +0.07% | $131B | 965-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $793.26 | -1.78% | $81.7B | 945-pillar |
| ARGX argenx SE | $984.04 | -1.82% | $61.2B | 975-pillar |
| UCBJY UCB S.A. | $117.06 | -1.42% | $44.6B | 679-signal |
| ALNY Alnylam Pharmaceuticals, Inc. | $247.51 | -4.07% | $33.1B | 895-pillar |
| RPRX Royalty Pharma plc | $58.75 | -3.04% | $26.0B | 725-pillar |
| INCY Incyte Corporation | $121.47 | -1.47% | $24.6B | 985-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are CHNXF's Key Strengths?
Proprietary biopolymer technology platform.
- Focus on a growing market segment (orthopaedic biologics).
- Pipeline of product candidates targeting various soft tissue injuries.
- Experienced management team with expertise in regenerative medicine.
What Are CHNXF's Weaknesses?
Early-stage company with limited revenue.
- Reliance on successful clinical trial outcomes.
- Dependence on external funding.
- OTC market listing, which can limit liquidity and investor access.
What Could Drive CHNXF Stock Higher?
Clinical trial results for Ortho-R in rotator cuff repair.
- Regulatory submissions for Ortho-M in meniscus repair.
- Development of Ortho-C for articular cartilage repair.
- Potential partnerships with orthopaedic device companies.
- Expansion into international markets.
What Are the Key Risks for CHNXF?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Unsuccessful clinical trial outcomes.
- Regulatory delays or rejections.
- Competition from established orthopaedic companies.
- Dependence on external funding.
- OTC market listing, which can limit liquidity and investor access.
What Are the Growth Opportunities for CHNXF?
- Expansion of Ortho-R into the U.S. market: The rotator cuff repair market represents a significant opportunity for ChitogenX. Successfully navigating the FDA approval process and establishing a distribution network in the U.S. could drive substantial revenue growth. The U.S. market for rotator cuff repair is estimated to be worth hundreds of millions of dollars annually, offering a large addressable market for Ortho-R.
- Advancement of Ortho-M through clinical trials: Meniscus tears are a common sports-related injury, and Ortho-M has the potential to offer a novel treatment option. Positive results from clinical trials could attract partnerships with larger orthopaedic companies and accelerate commercialization. The market for meniscus repair is growing, driven by increasing sports participation and an aging population.
- Development of Ortho-C for articular cartilage repair: Articular cartilage damage is a significant cause of pain and disability. Ortho-C aims to address this unmet need with a biopolymer formulation designed to promote cartilage regeneration. Successful development and commercialization of Ortho-C could open up a new market segment for ChitogenX.
- Strategic partnerships with orthopaedic device companies: Collaborating with established orthopaedic device companies could provide ChitogenX with access to their distribution networks, marketing expertise, and regulatory support. These partnerships could accelerate the commercialization of ChitogenX's products and expand its market reach.
- Expansion into international markets beyond Canada: While ChitogenX is currently focused on the Canadian market, expanding into other international markets could drive significant growth. Europe and Asia represent large opportunities for orthopaedic biologics, and ChitogenX could leverage its technology platform to enter these markets.
What Are CHNXF's Competitive Advantages?
- Proprietary biopolymer formulations.
- Patent protection for its technologies.
- First-mover advantage in specific market segments.
- Expertise in orthopaedic biologics.
What Does CHNXF Do?
ChitogenX Inc., formerly known as Ortho Regenerative Technologies Inc., was incorporated in 2015 and is headquartered in Kirkland, Canada. The company operates within the orthopaedic and sports medicine biologics sector, focusing on the research and development of innovative soft tissue repair technologies. ChitogenX aims to enhance the success rate of sports medicine surgeries through its proprietary biopolymer formulations. Their lead product candidates include Ortho-R, a formulation designed for rotator cuff repair, and Ortho-M, a biopolymer intended for meniscus repair. Additionally, the company is developing Ortho-C for articular cartilage repair, Ortho-V for osteoarthritis healing, and ORTHO-T for tendon healing and regeneration. These products are designed to address prevalent sports-related injuries and degenerative conditions, offering potential improvements over existing surgical techniques. The company changed its name to ChitogenX Inc. in September 2022, reflecting its commitment to regenerative medicine in orthopaedics.
What Products and Services Does CHNXF Offer?
- Develops Ortho-R for rotator cuff repair.
- Develops Ortho-M for meniscus repair.
- Develops Ortho-C for articular cartilage repair.
- Develops Ortho-V for osteoarthritis healing.
- Develops ORTHO-T for tendon healing and regeneration.
- Researches and develops novel therapeutic soft tissue repair technologies.
- Aims to enhance the success rate of sports medicine surgeries.
How Does CHNXF Make Money?
- Develops and patents biopolymer formulations for orthopaedic applications.
- Conducts preclinical and clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approvals for its products in various markets.
- Commercializes its products through direct sales, partnerships, or licensing agreements.
What Industry Does CHNXF Operate In?
The orthopaedic biologics market is experiencing growth driven by increasing demand for minimally invasive surgical procedures and regenerative medicine solutions. Companies like ChitogenX are positioned to capitalize on this trend by developing innovative therapies for soft tissue repair. The competitive landscape includes established players and emerging biotech firms, all vying for market share in specific segments such as rotator cuff repair, meniscus repair, and osteoarthritis treatment. The market is characterized by a focus on improving surgical outcomes, reducing recovery times, and enhancing the quality of life for patients with musculoskeletal conditions.
Who Are CHNXF's Key Customers?
- Orthopaedic surgeons.
- Sports medicine physicians.
- Hospitals and surgical centers.
- Patients with soft tissue injuries.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 680 days ago
- ● No analyst coverage
- ● Reported in CAD, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 45 |
| 2026-08-26 | 45 |
| 2026-08-29 | 45 |
| 2026-09-01 | 45 |
| 2026-09-04 | 45 |
| 2026-09-07 | 45 |
| 2026-09-10 | 45 |
What changed?
The score has stayed at 45.
Over the same 18 days the stock moved +0.0%.
ChitogenX Inc. Financial Trajectory
ChitogenX Inc. (CHNXF) reported $0 in revenue for Q3 FY2025, based on the latest filing compared to the prior quarter. The company recorded a net loss of $437K, with diluted EPS of $-0.01. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, CHNXF averaged $-0.00 in diluted EPS.
Company Profile
ChitogenX Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Kirkland, CA. The company is led by CEO Pierre Laurin. CHNXF has traded publicly since 2020.
Key Financial Metrics
Return on equity for ChitogenX Inc. stands at 19.4%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.07 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
ChitogenX Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Earnings Track Record
ChitogenX Inc. has beaten Wall Street's EPS estimate in 3 of its last 4 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 44.8% above estimates on average.
Forward Outlook
Wall Street analysts project ChitogenX Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.11.
CHNXF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Proprietary biopolymer technology platform.
- Focus on a growing market segment (orthopaedic biologics).
- Pipeline of product candidates targeting various soft tissue injuries.
- Experienced management team with expertise in regenerative medicine.
Bear Case
- Early-stage company with limited revenue.
- Reliance on successful clinical trial outcomes.
- Dependence on external funding.
- OTC market listing, which can limit liquidity and investor access.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 FY2025 | $0 | -$436,974.48 | -$0.01 |
| Q2 FY2025 | $0 | -$240,119.64 | -$0.0029 |
| Q1 FY2025 | $0 | -$113,209.56 | -$0.0014 |
| Q4 FY2024 | $0 | -$330,254.64 | -$0.0040 |
Q3 FY2025 · filed 31 Oct 2024 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from CAD at today's rate
CHNXF Latest News
No recent news available for CHNXF.
CHNXF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CHNXF.
Price Targets
Wall Street price target analysis for CHNXF.
CHNXF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CHNXF; grades run from A+ (80-100) to F (below 30).
Leadership: Pierre Laurin
CEO
Pierre Laurin is the CEO of ChitogenX Inc. His background includes extensive experience in the pharmaceutical and biotechnology industries. He has held leadership positions in various companies, focusing on business development, strategic planning, and commercialization of innovative healthcare products. He has a proven track record of driving growth and creating value for shareholders. His expertise spans across multiple therapeutic areas, including orthopaedics and regenerative medicine.
Track Record: Under Pierre Laurin's leadership, ChitogenX has focused on advancing its pipeline of soft tissue repair technologies. He has overseen the company's strategic shift towards regenerative medicine and has been instrumental in securing funding for clinical trials. Key milestones include the development of Ortho-R and Ortho-M, as well as the expansion of the company's intellectual property portfolio.
CHNXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that ChitogenX may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies on this tier may have limited financial reporting, potentially increasing investment risk compared to companies listed on major exchanges like the NYSE or NASDAQ, which have stringent listing standards and reporting requirements. This tier often includes companies with limited operating history or those facing financial difficulties.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Low trading volume can lead to price volatility.
- Higher risk of fraud or manipulation compared to listed exchanges.
- Limited regulatory oversight.
- Potential for delisting or trading suspensions.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and their experience.
- Evaluate the company's business model and competitive landscape.
- Review the company's intellectual property portfolio.
- Understand the company's capital structure and potential dilution.
- Check for any legal or regulatory issues.
- Consult with a financial advisor.
- Focus on research and development of innovative technologies.
- Experienced management team with relevant industry expertise.
- Patent protection for its biopolymer formulations.
- Collaboration with reputable research institutions.
- Presence of a clear business plan and strategic vision.
What Investors Ask About ChitogenX Inc. (CHNXF) — Healthcare
Is CHNXF a good stock?
Stock Expert AI does not rate CHNXF buy, sell or hold. ChitogenX Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What does ChitogenX Inc. do?
ChitogenX Inc. is an orthopaedic and sports medicine biologics company focused on developing and commercializing novel soft tissue repair technologies.
What are the key factors to evaluate for CHNXF?
Evaluate CHNXF on fundamentals, analyst consensus, and risk factors. Investors should closely monitor cash burn and potential dilution. Not financial advice.
How frequently does CHNXF data refresh on this page?
CHNXF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CHNXF's recent stock price performance?
ChitogenX Inc. (CHNXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary biopolymer technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CHNXF overvalued or undervalued right now?
ChitogenX Inc. (CHNXF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of CHNXF?
Yes, most major brokerages offer fractional shares of ChitogenX Inc. (CHNXF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CHNXF's earnings and financial reports?
ChitogenX Inc. (CHNXF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for CHNXF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for CHNXF.
- OTC market listing increases investment risk.